Details for Patent: 10,004,700
✉ Email this page to a colleague
Which drugs does patent 10,004,700 protect, and when does it expire?
Patent 10,004,700 protects EPINEPHRINE and is included in one NDA.
Summary for Patent: 10,004,700
Title: | More potent and less toxic formulations of epinephrine and methods of medical use |
Abstract: | The present invention provides pharmaceutical formulations of levorotatory-epinephrine, l-epinephrine, more potent and less toxic than existing pharmaceutical formulations of epinephrine, along with methods of producing and using these pharmaceutical formulations of l-epinephrine, including autoinjection for treating anaphylaxis. |
Inventor(s): | Taneja; Jugal K. (Tampa, FL) |
Assignee: | |
Application Number: | 15/596,440 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 10,004,700 |
Patent Claim Types: see list of patent claims | Use; Formulation; Compound; Device; Dosage form; |
Drugs Protected by US Patent 10,004,700
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bpi Labs | EPINEPHRINE | epinephrine | SOLUTION;INTRAVENOUS, INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS | 205029-001 | Jul 29, 2014 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | EMERGENCY TREATMENT OF ALLERGIC REACTIONS (TYPE 1), INCLUDING ANAPHYLAXIS; A METHOD OF TREATING ALLERGIC REACTION, ANAPHYLAXIS, ANAPHYLACTIC SHOCK, OR COMBINATION THEREOF BY AN INJECTION OF AT LEAST ONE DOSAGE OF THE INJECTABLE LIQUID PHARMACEUTICAL | ⤷ Sign Up | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |